Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -268.09% is 92% below its 5-year average of -139.59%, around the middle of its 5-year range (-612.79%–-9.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 22.86% above its 12-month average of -347.51%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -268.09%.
RETURN ON EQUITY (ROE)
-268.09%
RETURN ON EQUITY (ROE) AVG TTM
-347.51%
RETURN ON EQUITY (ROE) AVG 3Y
-202.29%
RETURN ON EQUITY (ROE) AVG 5Y
-139.59%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.86%
CURRENT VS 3Y AVG
-32.53%
CURRENT VS 5Y AVG
-92.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.33%
median of 447 covered companies
CURRENT VS SECTOR MEDIAN
-599.42%
vs the sector median at left
Biomea Fusion, Inc.
Market Cap
$92.54M
Return on Equity (ROE)
-268.09%
TTM Avg
-347.51%
3Y Avg
-202.29%
5Y Avg
-139.59%
Market Cap
$92.41M
Return on Equity (ROE)
N/A
TTM Avg
329.82%
3Y Avg
69.21%
5Y Avg
21.28%
Market Cap
$88.97M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$88.63M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
Market Cap
$88.21M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
Market Cap
$87.96M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$87.88M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
Market Cap
$99.01M
Return on Equity (ROE)
-72.02%
TTM Avg
-67.42%
3Y Avg
-55.49%
5Y Avg
-62.36%
Market Cap
$101.52M
Return on Equity (ROE)
-103.31%
TTM Avg
-140.03%
3Y Avg
-67.31%
5Y Avg
-49.97%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | $92.54M | -268.09% | -347.51% | -202.29% | -139.59% |
| electroCore, Inc. (ECOR)vs › | $92.41M | N/A | 329.82% | 69.21% | 21.28% |
| Conexeu Sciences Inc. (CNXU)vs › | $88.97M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | -150.95% | -77.89% | -62.90% | -47.80% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 2.51% | -5.84% | -10.75% | -7.81% |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 45.93% | 16.96% | -19.36% | -13.87% |
| Equillium, Inc. (EQ)vs › | $87.88M | -32.15% | -60.32% | -93.79% | -79.41% |
| Anixa Biosciences, Inc. (ANIX)vs › | $99.01M | -72.02% | -67.42% | -55.49% | -62.36% |
| Korro Bio, Inc. (KRRO)vs › | $101.52M | -103.31% | -140.03% | -67.31% | -49.97% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.60M | -85.65% | -57.41% | -45.73% | -8.61% |
ROE
-268.1%
ROA
-88.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -268.09% |
| 2026-03-31 | -240.13% |
| 2025-12-31 | -209.11% |
| 2025-09-30 | -612.79% |
| 2025-06-30 | -407.46% |
| 2025-03-31 | -447.60% |
| 2024-12-31 | -268.41% |
| 2024-09-30 | -189.55% |
| 2024-06-30 | -134.35% |
| 2024-03-31 | -94.05% |
| 2023-12-31 | -69.28% |
| 2023-09-30 | -53.95% |
| 2023-06-30 | -45.54% |
| 2023-03-31 | -113.69% |
| 2022-12-31 | -75.39% |
| 2022-09-30 | -54.52% |
| 2022-06-30 | -40.52% |
| 2022-03-31 | -31.61% |
| 2021-12-31 | -23.25% |
| 2021-09-30 | -15.87% |
| 2021-06-30 | -9.35% |
| 2020-12-31 | -103.00% |
